Pilot Projects Program
试点项目计划
基本信息
- 批准号:10281520
- 负责人:
- 金额:$ 39.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-18 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAldosteroneAreaAwardCardiovascular DiseasesClinicalClinical ResearchCollaborationsCollectionCommunicable DiseasesCommunitiesCommunity OutreachCultural BackgroundsDataData CollectionDevelopmentDiabetes MellitusEconomically Deprived PopulationEndocrinologyExpenditureExtramural ActivitiesFacultyFundingGoalsGrantHealthHealth PrioritiesHealth Services AccessibilityHomeIndividualInfrastructureInstitutionKidney DiseasesLeadLearningMalignant NeoplasmsMaternal HealthMedical centerMentorsMineralocorticoidsMississippiMonitorNCI Scholars ProgramNamesObesityObesity associated diseaseOutcomePhasePilot ProjectsPopulation ResearchProbabilityProcessProgram DevelopmentRegulationResearchResearch PersonnelResearch Project GrantsResearch SupportResourcesReview LiteratureRoleRuralSeedsStudy SectionTimeTrainingTranslational ResearchUnited States National Institutes of HealthUniversitiesWorkbasecareercareer developmentclinical centercollegecommunity based participatory researchcommunity engaged researchcommunity engagementethnic diversityexpectationgender diversityhealth disparityimprovedinterestmedically underserved populationmeetingsmembermultidisciplinaryobesity managementoutreachprogramssuccesssummer institute
项目摘要
PROJECT SUMMARY- PILOT PROJECTS PROGRAM. Central to realizing the MCCTR's purpose of
expanding Mississippi's capacity for clinical, translational, and community research is its Pilot Projects Program
(PPP). The PPP supports clinical, translational, and population research projects that will become the basis for
competitive extramural funding applications. During Phase I, key considerations in awarding support to early
stage investigators included the (1) likelihood of attracting extramural funding, (2) evidence of a path toward an
independent research career for the applicant, and (3) probability that the research program would lead to
improved management of obesity or obesity-related diseases. Additional considerations included support for
ethnic and gender diversity, promoting multi-disciplinary and multi-institutional research projects, and equitable
distribution of resources across the MCCTR partner institutions. During Phase II, the breadth of PPP's initiatives
will be expanded in several ways. First, the focus of our pilot project awards will be expanded to include health
conditions such as obesity, diabetes, cardiovascular and renal disease, cancer, infectious diseases, and
maternal health, all of which are disproportionally prevalent in rural and economically disadvantaged areas of
our state. Second, the number of institutions of higher learning eligible to participate in open solicitation for
applications will be expanded to include Tougaloo College, University of Southern Mississippi, the University of
Mississippi Medical Center, and our new members, Mississippi State University and the University of Mississippi
in Oxford. Third, a new funding program that provides up to $5,000 in seed money to support multi-institutional
collaboration and preliminary data collection for development of a subsequent proposal to the PPP and
elsewhere will be introduced. The PPP will solicit applications for funding two times per year to support
investigator-initiated clinical and translational research of priority health areas within Mississippi, including
community-engaged research addressing Mississippi's health disparities and access-to-care issues, with the
expectation of funding up to seven pilot projects per year. Applications for the seed grant program will be solicited
four times per year through an expedited application and review process. For all programs, studies addressing
health disparities and medically underserved populations with an emphasis on implementation will be prioritized.
The PPP and its related programs will lead to support for multi-institutional and multi-disciplinary collaborative
research among strong investigators from diverse academic and cultural backgrounds. Overall, this approach
will lead to a broad-based, state-wide research platform that has the capacity to improve health outcomes and
address health disparities across Mississippi.
项目概要----试点项目实现MCCTR目标的核心是
扩大密西西比临床、转化和社区研究的能力是其试点项目计划
(购买力平价)。PPP支持临床,转化和人口研究项目,这些项目将成为
有竞争力的校外资助申请。在第一阶段,向早期发展提供支助的主要考虑因素
阶段调查包括(1)吸引校外资金的可能性,(2)通往
申请人的独立研究生涯,以及(3)研究计划将导致
改善肥胖症或肥胖相关疾病的管理。其他考虑包括支持
种族和性别多样性,促进多学科和多机构的研究项目,
在MCCTR伙伴机构之间分配资源。在第二阶段,公私伙伴关系举措的广度
将以多种方式扩展。首先,我们的试点项目奖励的重点将扩大到包括健康
如肥胖症、糖尿病、心血管和肾脏疾病、癌症、传染病和
孕产妇保健,所有这些疾病在农村和经济贫困地区都很普遍,
我们的国家。二是有资格参加公开征集的高等学校数量
申请将扩大到包括Tougaloo学院,南密西西比大学,
密西西比医学中心,以及我们的新成员,密西西比州立大学和密西西比大学
在牛津第三,一个新的资助计划,提供高达5,000美元的种子资金,以支持多机构
合作和初步数据收集,以制定随后的PPP提案,
将在其他地方推出。公私营界别合作计划每年会接受两次拨款申请,
在密西西比州内的优先健康领域开展由州政府发起的临床和转化研究,包括
社区参与的研究,解决密西西比的健康差距和获得保健问题,与
预计每年资助多达7个试点项目。种子赠款计划的申请将征求
每年四次,通过快速申请和审查程序。对于所有方案,研究解决
将优先重视健康差距和医疗服务不足的人口,重点是执行。
公私伙伴关系及其相关计划将支持多机构和多学科的合作
来自不同学术和文化背景的强大研究人员之间的研究。总的来说,这种方法
将导致一个基础广泛的,全州范围的研究平台,有能力改善健康结果,
解决密西西比州的健康差距。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Celso Enrique Gomez-Sanchez其他文献
Celso Enrique Gomez-Sanchez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Celso Enrique Gomez-Sanchez', 18)}}的其他基金
Regulation of Mineralocorticoid Receptor Action
盐皮质激素受体作用的调节
- 批准号:
10553631 - 财政年份:2020
- 资助金额:
$ 39.78万 - 项目类别:
Regulation of Mineralocorticoid Receptor Action
盐皮质激素受体作用的调节
- 批准号:
10293532 - 财政年份:2020
- 资助金额:
$ 39.78万 - 项目类别:
Regulation of Mineralocorticoid Receptor Action
盐皮质激素受体作用的调节
- 批准号:
10436926 - 财政年份:2020
- 资助金额:
$ 39.78万 - 项目类别:
Adrenal cell ATP1A1 mutations and mechanisms of aldosterone biosynthesis
肾上腺细胞ATP1A1突变与醛固酮生物合成机制
- 批准号:
9981536 - 财政年份:2019
- 资助金额:
$ 39.78万 - 项目类别:
Adrenal cell ATP1A1 mutations and mechanisms of aldosterone biosynthesis
肾上腺细胞ATP1A1突变与醛固酮生物合成机制
- 批准号:
10447775 - 财政年份:2019
- 资助金额:
$ 39.78万 - 项目类别:
Adrenal cell ATP1A1 mutations and mechanisms of aldosterone biosynthesis
肾上腺细胞ATP1A1突变与醛固酮生物合成机制
- 批准号:
9813129 - 财政年份:2019
- 资助金额:
$ 39.78万 - 项目类别:
Adrenal cell ATP1A1 mutations and mechanisms of aldosterone biosynthesis
肾上腺细胞ATP1A1突变与醛固酮生物合成机制
- 批准号:
10210433 - 财政年份:2019
- 资助金额:
$ 39.78万 - 项目类别:
Regulation of the late-pathway of aldosterone biosynthesis
醛固酮生物合成后期途径的调节
- 批准号:
8254384 - 财政年份:2011
- 资助金额:
$ 39.78万 - 项目类别:
相似海外基金
In vivo and ex vivo lessons from somatic adrenal mutations in cell adhesion molecule 1 for physiological and pathological production of aldosterone
细胞粘附分子 1 体细胞肾上腺突变对醛固酮生理和病理产生的体内和离体教训
- 批准号:
MR/X018970/1 - 财政年份:2023
- 资助金额:
$ 39.78万 - 项目类别:
Fellowship
Creating therapeutic strategies targeting both aldosterone and AGEs-RAGE axis for stopping kidney diseases progression
制定针对醛固酮和 AGEs-RAGE 轴的治疗策略,以阻止肾脏疾病的进展
- 批准号:
23K15240 - 财政年份:2023
- 资助金额:
$ 39.78万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Processivity and Catalytic Mechanism of Aldosterone Synthase
醛固酮合酶的持续合成能力和催化机制
- 批准号:
10600520 - 财政年份:2023
- 资助金额:
$ 39.78万 - 项目类别:
Aldosterone/mineralocorticoid receptor responses to biologic sex and salt intake: Role of Lysine Specific Demethylase 1 (LSD1)
醛固酮/盐皮质激素受体对生物性别和盐摄入量的反应:赖氨酸特异性脱甲基酶 1 (LSD1) 的作用
- 批准号:
10930190 - 财政年份:2023
- 资助金额:
$ 39.78万 - 项目类别:
Development of a CYP11B2 probe for imaging aldosterone-producing adenomas with high sensitivity.
开发用于高灵敏度对产生醛固酮的腺瘤进行成像的 CYP11B2 探针。
- 批准号:
23H02850 - 财政年份:2023
- 资助金额:
$ 39.78万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Aldosterone blockade for Health Improvement Evaluation in End-stage kidney disease: Extension
醛固酮阻断用于终末期肾病健康改善评估:延伸
- 批准号:
461992 - 财政年份:2022
- 资助金额:
$ 39.78万 - 项目类别:
Operating Grants
Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure
利钠肽-肾素-血管紧张素-醛固酮系统节律轴与夜间血压
- 批准号:
10545747 - 财政年份:2022
- 资助金额:
$ 39.78万 - 项目类别:
Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure
利钠肽-肾素-血管紧张素-醛固酮系统节律轴与夜间血压
- 批准号:
10342142 - 财政年份:2022
- 资助金额:
$ 39.78万 - 项目类别:
Role of Renin-Angiotensin-Aldosterone System during sarcoidosis granuloma formation
肾素-血管紧张素-醛固酮系统在结节病肉芽肿形成过程中的作用
- 批准号:
10591934 - 财政年份:2022
- 资助金额:
$ 39.78万 - 项目类别:
Association between excessive salt intake and brain renin-angiotensin-aldosterone system in obesity.
肥胖中过量盐摄入与脑肾素-血管紧张素-醛固酮系统之间的关联。
- 批准号:
22K08167 - 财政年份:2022
- 资助金额:
$ 39.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)